Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
ZacksZevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -2.13% and 8.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?